HSBC Downgrades AstraZeneca to Hold AstraZeneca (NASDAQ:AZN) shares moved lower on Monday after HSBC downgraded the ...
By Andrew Silver SHANGHAI, July 14 (Reuters) - Shares in China's Dizal Pharmaceutical rose 20% on Tuesday, after the ...
7don MSN
AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.
UBS expects AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to report solid second-quarter results later this month, though it sees ...
Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and ...
Harris Oakmark recently released its second-quarter 2026 investor letter for the “Oakmark Global Fund”. A copy of the letter ...
Abbisko will lead the study, with both companies jointly sharing clinical trial responsibilities.
By Raechel Thankam Job July 9 (Reuters) - AstraZeneca's nerve disease drug Wainua, made in partnership with Ionis, ...
AstraZeneca pays $600M for global rights to Dizal’s lung cancer drug Zegfrovy, boosting its oncology pipeline.
Wainua’s ATTR-CM failure is a setback for the AstraZeneca program, but it doesn’t kill the underlying platform value: Ionis ...
AstraZeneca has added another piece to its sprawling interface with CSPC Pharmaceutical, paying the Chinese biotech $30 million upfront to jointly discover and develop two kidney disease drug ...
J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results